JP2024520927A - オリゴヌクレオチドプールからの遺伝子アセンブリー - Google Patents
オリゴヌクレオチドプールからの遺伝子アセンブリー Download PDFInfo
- Publication number
- JP2024520927A JP2024520927A JP2023569973A JP2023569973A JP2024520927A JP 2024520927 A JP2024520927 A JP 2024520927A JP 2023569973 A JP2023569973 A JP 2023569973A JP 2023569973 A JP2023569973 A JP 2023569973A JP 2024520927 A JP2024520927 A JP 2024520927A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- iisre
- acid molecules
- adamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 46
- 108091034117 Oligonucleotide Proteins 0.000 title description 35
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 318
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 255
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 255
- 238000000034 method Methods 0.000 claims abstract description 161
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 239000012634 fragment Substances 0.000 claims description 95
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 56
- 230000000295 complement effect Effects 0.000 claims description 49
- 102000003960 Ligases Human genes 0.000 claims description 41
- 108090000364 Ligases Proteins 0.000 claims description 41
- 108091023037 Aptamer Proteins 0.000 claims description 30
- 108091008146 restriction endonucleases Proteins 0.000 claims description 29
- 108060002716 Exonuclease Proteins 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 102000013165 exonuclease Human genes 0.000 claims description 28
- 230000002194 synthesizing effect Effects 0.000 claims description 20
- 102000010645 MutS Proteins Human genes 0.000 claims description 16
- 108010038272 MutS Proteins Proteins 0.000 claims description 16
- 108091033409 CRISPR Proteins 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 8
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020005004 Guide RNA Proteins 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000002515 oligonucleotide synthesis Methods 0.000 abstract description 14
- 238000001308 synthesis method Methods 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 9
- 230000006820 DNA synthesis Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000002773 nucleotide Substances 0.000 description 160
- 125000003729 nucleotide group Chemical group 0.000 description 155
- 239000000047 product Substances 0.000 description 145
- 239000007787 solid Substances 0.000 description 80
- 241000894007 species Species 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 25
- 238000013461 design Methods 0.000 description 23
- 238000010586 diagram Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 108010055863 gene b exonuclease Proteins 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 8
- 108010061982 DNA Ligases Proteins 0.000 description 8
- 102000012410 DNA Ligases Human genes 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000002966 oligonucleotide array Methods 0.000 description 7
- 238000000429 assembly Methods 0.000 description 6
- 230000000712 assembly Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000007702 DNA assembly Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091027757 Deoxyribozyme Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- GOMLCFUVZKLQCO-HTLAMOOLSA-N thrombin aptamer Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 GOMLCFUVZKLQCO-HTLAMOOLSA-N 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710178665 Error-prone DNA polymerase Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AEIMYPLMACPBOD-UHFFFAOYSA-N carbonocyanidic acid;nickel Chemical compound [Ni].OC(=O)C#N AEIMYPLMACPBOD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186871P | 2021-05-11 | 2021-05-11 | |
| US63/186,871 | 2021-05-11 | ||
| PCT/US2022/028775 WO2022240991A1 (en) | 2021-05-11 | 2022-05-11 | Gene assembly from oligonucleotide pools |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520927A true JP2024520927A (ja) | 2024-05-27 |
| JP2024520927A5 JP2024520927A5 (https=) | 2025-05-20 |
Family
ID=82016194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569973A Pending JP2024520927A (ja) | 2021-05-11 | 2022-05-11 | オリゴヌクレオチドプールからの遺伝子アセンブリー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240247256A1 (https=) |
| EP (1) | EP4337775A1 (https=) |
| JP (1) | JP2024520927A (https=) |
| KR (1) | KR20240005893A (https=) |
| CN (1) | CN117677702A (https=) |
| AU (1) | AU2022274239A1 (https=) |
| CA (1) | CA3218247A1 (https=) |
| WO (1) | WO2022240991A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025120370A1 (en) * | 2023-12-08 | 2025-06-12 | Camena Bioscience Limited | Compositions and methods for solution-phase, phosphoramidite-free synthesis of nucleic acids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737755B1 (en) * | 2018-01-12 | 2024-08-28 | Camena Bioscience Limited | Method for template-free geometric enzymatic nucleic acid synthesis |
| WO2020150143A2 (en) * | 2019-01-14 | 2020-07-23 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
| WO2021055962A1 (en) | 2019-09-19 | 2021-03-25 | Camena Bioscience Limited | Compositions and methods for template-free double stranded geometric enzymatic nucleic acid synthesis |
-
2022
- 2022-05-11 JP JP2023569973A patent/JP2024520927A/ja active Pending
- 2022-05-11 US US18/560,445 patent/US20240247256A1/en active Pending
- 2022-05-11 CA CA3218247A patent/CA3218247A1/en active Pending
- 2022-05-11 CN CN202280048699.1A patent/CN117677702A/zh active Pending
- 2022-05-11 EP EP22729349.5A patent/EP4337775A1/en active Pending
- 2022-05-11 KR KR1020237042226A patent/KR20240005893A/ko active Pending
- 2022-05-11 WO PCT/US2022/028775 patent/WO2022240991A1/en not_active Ceased
- 2022-05-11 AU AU2022274239A patent/AU2022274239A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN117677702A (zh) | 2024-03-08 |
| CA3218247A1 (en) | 2022-11-17 |
| US20240247256A1 (en) | 2024-07-25 |
| WO2022240991A1 (en) | 2022-11-17 |
| EP4337775A1 (en) | 2024-03-20 |
| AU2022274239A1 (en) | 2023-11-23 |
| KR20240005893A (ko) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2971034B1 (en) | Compositions, methods and apparatus for oligonucleotides synthesis | |
| EP2943579B1 (en) | Libraries and methods for generating molecules | |
| EP4524259B1 (en) | Controlled strand-displacement for paired-end sequencing | |
| CA2982421A1 (en) | Compositions and methods for constructing strand specific cdna libraries | |
| EP4347872B1 (en) | Oligo-modified nucleotide analogues for nucleic acid preparation | |
| JP2024520927A (ja) | オリゴヌクレオチドプールからの遺伝子アセンブリー | |
| US20240209407A1 (en) | Compositions and methods for phosphoramidite-free enzymatic synthesis of nucleic acids | |
| WO2025024703A1 (en) | Dual-tagmentation single-cell dnaseq | |
| JP2024520927A5 (https=) | ||
| EP4623103B1 (en) | Methods for obtaining correctly assembled nucleic acids | |
| Wu | Development of Enzyme‐Based Methods for DNA Sequence Analysis and their Applications in the Genome Projects | |
| HK40122432A (en) | Controlled strand-displacement for paired-end sequencing | |
| CN121065310A (zh) | 用于在单细胞实验中对分子加条形码的方法 | |
| CN113699215A (zh) | 一种核酸适体筛选方法 | |
| CN119546761A (zh) | 大小受控的核酸片段的制备 | |
| CN119432977A (zh) | 一种富集目标核酸的方法和试剂盒 | |
| CN107937389A (zh) | 阵列上连接组装 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250206 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250509 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250509 |